JP2022095908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022095908A5 JP2022095908A5 JP2022067540A JP2022067540A JP2022095908A5 JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5 JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- her2
- antibody
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016749A JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2025201784A JP2026035673A (ja) | 2016-10-07 | 2025-11-21 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016199341 | 2016-10-07 | ||
| JP2016199341 | 2016-10-07 | ||
| JP2017097589 | 2017-05-16 | ||
| JP2017097589 | 2017-05-16 | ||
| JP2017172814 | 2017-09-08 | ||
| JP2017172814 | 2017-09-08 | ||
| PCT/JP2017/036215 WO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2018543951A JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Division JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016749A Division JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022095908A JP2022095908A (ja) | 2022-06-28 |
| JP2022095908A5 true JP2022095908A5 (https=) | 2023-03-08 |
Family
ID=61831486
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Pending JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
| JP2022067540A Pending JP2022095908A (ja) | 2016-10-07 | 2022-04-15 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2024016749A Withdrawn JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2025201784A Pending JP2026035673A (ja) | 2016-10-07 | 2025-11-21 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Pending JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016749A Withdrawn JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2025201784A Pending JP2026035673A (ja) | 2016-10-07 | 2025-11-21 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190330368A1 (https=) |
| EP (1) | EP3524267A4 (https=) |
| JP (4) | JPWO2018066626A1 (https=) |
| KR (2) | KR20190066026A (https=) |
| CN (1) | CN109789211A (https=) |
| AU (2) | AU2017341000B2 (https=) |
| BR (1) | BR112019005247A2 (https=) |
| CA (1) | CA3036941C (https=) |
| SG (1) | SG10201912173RA (https=) |
| TW (2) | TWI827534B (https=) |
| WO (1) | WO2018066626A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018320470B2 (en) * | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| US20190194348A1 (en) * | 2017-11-10 | 2019-06-27 | Oregon Health & Science University | Treatment of therapy-resistant her-2 positive breast cancer |
| IL278988B2 (en) | 2018-05-28 | 2024-10-01 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer |
| SG11202100653YA (en) * | 2018-07-25 | 2021-02-25 | Daiichi Sankyo Co Ltd | Effective method for manufacturing antibody-drug conjugate |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| CA3108044A1 (en) | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| EP3848054B1 (en) | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| EP4058024A1 (en) | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| WO2021173773A1 (en) | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
| JP7848119B2 (ja) | 2020-07-20 | 2026-04-20 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |
| JP2023551355A (ja) * | 2020-09-30 | 2023-12-08 | デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド | 抗腫瘍化合物並びにその調製方法及び使用 |
| KR102247908B1 (ko) * | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| CN116583526B (zh) * | 2020-12-11 | 2025-09-26 | 微境生物医药科技(上海)有限公司 | 新型喜树碱衍生物、含其的组合物和其用途 |
| US12521444B2 (en) * | 2021-02-25 | 2026-01-13 | Fortvita Biologics Limited | Anti-HER2 antibody-drug conjugates and uses thereof |
| EP4346908A4 (en) * | 2021-05-24 | 2026-04-29 | Remegen Co Ltd | USE OF AN ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN THE TREATMENT OF LOW-EXPRESSING HER2 BREAST CANCER |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2024008102A1 (en) * | 2022-07-05 | 2024-01-11 | Wuxi Xdc (Shanghai) Co., Ltd. | Linker for conjugation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CN1191093C (zh) | 1998-10-30 | 2005-03-02 | 第一制药株式会社 | Dds化合物及其测定方法 |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| BR0012196A (pt) | 1999-06-25 | 2002-03-19 | Genentech Inc | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
-
2017
- 2017-10-05 KR KR1020197011914A patent/KR20190066026A/ko not_active Ceased
- 2017-10-05 KR KR1020237038566A patent/KR20230158641A/ko not_active Ceased
- 2017-10-05 JP JP2018543951A patent/JPWO2018066626A1/ja active Pending
- 2017-10-05 CN CN201780062054.2A patent/CN109789211A/zh active Pending
- 2017-10-05 CA CA3036941A patent/CA3036941C/en active Active
- 2017-10-05 US US16/334,008 patent/US20190330368A1/en active Pending
- 2017-10-05 AU AU2017341000A patent/AU2017341000B2/en active Active
- 2017-10-05 SG SG10201912173RA patent/SG10201912173RA/en unknown
- 2017-10-05 BR BR112019005247A patent/BR112019005247A2/pt unknown
- 2017-10-05 WO PCT/JP2017/036215 patent/WO2018066626A1/ja not_active Ceased
- 2017-10-05 EP EP17858462.9A patent/EP3524267A4/en active Pending
- 2017-10-06 TW TW106134472A patent/TWI827534B/zh active
- 2017-10-06 TW TW111125911A patent/TWI868465B/zh active
-
2022
- 2022-04-15 JP JP2022067540A patent/JP2022095908A/ja active Pending
-
2024
- 2024-02-07 JP JP2024016749A patent/JP2024054226A/ja not_active Withdrawn
-
2025
- 2025-02-13 AU AU2025201016A patent/AU2025201016A1/en active Pending
- 2025-11-21 JP JP2025201784A patent/JP2026035673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022095908A5 (https=) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2025041725A5 (https=) | ||
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2020525542A5 (https=) | ||
| AU2019278628B2 (en) | Treatment of HER2-mutated cancer by administering anti-HER2 antibody-drug conjugate | |
| JP2020512314A5 (https=) | ||
| JP2023525120A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2021515017A5 (https=) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| JP2023510349A5 (https=) | ||
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2006265245A5 (https=) | ||
| JP2019524713A5 (https=) | ||
| JP7449583B2 (ja) | 標的特異的複合体及びその用途 | |
| JP2024542095A5 (https=) | ||
| JP2024536383A5 (https=) | ||
| CN112043832A (zh) | 用于联合治疗胃癌的喹啉类化合物 | |
| JP2025517908A5 (https=) | ||
| JP2024502465A5 (https=) | ||
| CA3122946C (en) | Combination of antibody-drug conjugate with parp inhibitor | |
| JP2020527594A5 (https=) |